USPTO serial 79380366
AUTOLUS
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Jul 9, 2024
- Examiner
- STADELI, MARTA ANN
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with AUTOLUS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Rebecca Liebowitz
Rebecca Liebowitz Venable LLPP.O. Box 34385Washington, DC 20043-9998United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Medical and veterinary preparations for therapeutic purposes for the treatment of cancer, genetic conditions, immune response disorders, autoimmune disorders, infectious diseases, ophthalmological conditions, hematologic diseases, neurological disorders, respiratory diseases, metabolic diseases and cardiovascular diseases; medical preparations for cell therapy for the treatment of cancer, genetic conditions, immune response disorders, autoimmune disorders, infectious diseases, ophthalmological conditions, hematologic diseases, neurological disorders, respiratory diseases, metabolic diseases and cardiovascular diseases; medical preparations for gene therapy for the treatment of cancer, genetic conditions, immune response disorders, autoimmune disorders, infectious diseases, ophthalmological conditions, hematologic diseases, neurological disorders, respiratory diseases, metabolic diseases and cardiovascular diseases; medical preparations for cancer therapies for the treatment of cancer, genetic conditions, immune response disorders, autoimmune disorders, infectious diseases, ophthalmological conditions, hematologic diseases, neurological disorders, respiratory diseases, metabolic diseases and cardiovascular diseases; cells for medical or clinical use, namely, cells featuring chimeric antigen receptors (CAR) and therapeutic preparations thereof for the treatment of cancer, genetic conditions, immune response disorders, autoimmune disorders, infectious diseases, ophthalmological conditions, hematologic diseases, neurological disorders, respiratory diseases, metabolic diseases and cardiovascular diseases; antibodies for medical purposes for the treatment of cancer, genetic conditions, immune response disorders, autoimmune disorders, infectious diseases, ophthalmological conditions, hematologic diseases, neurological disorders, respiratory diseases, metabolic diseases and cardiovascular diseases; preparations for genetically modifying human or animal cells for medical purposes, including viral vectors, namely, culture media for cultivating and augmentation of human and animal cells; preparations of blood extracted from humans or animals which have been adapted for therapeutic purposes; vaccines | ACTIVE | — |
| 040 | Custom manufacture of therapeutic drugs, namely, cell therapies, cancer therapies and cancer vaccines | ACTIVE | — |
| 042 | Scientific and technological services and research and design relating thereto, namely, medical research, scientific research, analysis and testing in the field of human and animal cell, gene and cancer therapies, pharmaceutical product development, research and development of new products; industrial analysis and research services in the field of cell, gene and cancer therapies; medical and veterinary research services including the manipulation of cells within a laboratory or research facility to enable the cells to be used for therapeutic purposes; scientific research in the development of new cancer therapies; scientific research in human and animal cell therapy; scientific research in human and animal gene therapy; scientific research into vaccines, including personalised cancer vaccines; scientific research into vectors and preparations for manipulating and adapting human and animal cells; consultancy relating to all the aforesaid services | ACTIVE | — |
| 044 | Medical services; veterinary services; medical and veterinary services in the nature of extraction of human and animal cells from patients; manipulation of human and animal cells for therapeutic purposes, namely, medical services relating to the removal, treatment and processing of human and animal cells; medical and veterinary services in the nature of reinsertion of cells into human and animal patients; providing medical advice and consultancy in the field of medical and veterinary therapies; providing advice and consultancy in the field of cancer therapies and cancer vaccines | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Autolus Limited
- Other trademarks owned by Autolus Limited
- Other trademarks owned by Autolus Limited
- Other trademarks in Class 005
- Other trademarks in Class 040
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named AUTOLUS
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Mar 22, 2025 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Mar 4, 2025 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Mar 4, 2025 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Mar 1, 2025 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Mar 1, 2025 | ECDR | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | — |
| Mar 1, 2025 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 1, 2025 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Jan 10, 2025 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Dec 20, 2024 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Dec 20, 2024 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Oct 10, 2024 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Jul 9, 2024 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Jul 9, 2024 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Apr 23, 2024 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Apr 23, 2024 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Apr 3, 2024 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Mar 16, 2024 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Mar 5, 2024 | RFNT | REFUSAL PROCESSED BY IB | — |
| Mar 1, 2024 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Feb 29, 2024 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Feb 29, 2024 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Feb 14, 2024 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Feb 14, 2024 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Jan 26, 2024 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Jan 25, 2024 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 25, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| Oct 14, 2023 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Oct 10, 2023 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Oct 5, 2023 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |